Cancer susceptibility 19 (CASC19)

Cancer susceptibility 19 (CASC19), also known by several aliases, is a long non-coding RNA (lncRNA) strongly implicated in cancer biology and prognosis, particularly as an oncogenic regulatory element. It is not a protein, receptor, enzyme, or classic drug target, but rather an RNA gene influencing cancer susceptibility and progression. Cancer susceptibility 19 (CASC19) is a long non-coding RNA gene located at chromosome 8q24.21, containing 324 nucleotides[1][2][6][8]. Highly conserved and selectively overexpressed in multiple cancer types, CASC19 regulates oncogenic processes such as cell proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition, autophagy, and therapy resistance[2][6][8]. The regulatory role of CASC19 is linked to genetic variants in the 8q24.21 region, and CASC19 is increasingly viewed as both a promising biomarker for cancer prognosis and a candidate for targeted RNA-based therapeutics[2][6][8].

Other names

CARLO-6CARLo-6CARLO4CARLo-4LINC01245PCA2TCONS_00015167Cancer-associated region long noncoding RNA 4Prostate cancer associated transcript 2 (non-protein coding)PCAT2

Potential inhibition via antisense oligonucleotides or RNA interference aimed at reducing CASC19 expression to limit oncogenic effects (investigational)